She joined Novartis more than 20 years ago and has led several of the company’s oncology businesses over the last six years, including region head of Novartis Oncology Europe.

For Novartis, oncology is a key strategic area, but it is still short of dominating the field. It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Novartis didn’t have the best experience with bispecifics in oncology. The company paid Xencor $150 million upfront in 2016 to co-develop two CD3 T-cell engaging bispecifics, only to have ...

According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Legos joins the Big Pharma from Novartis, where he served as executive vice president and global head of oncology and hematology development. Before that, Legos held various leadership roles at GSK.

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

The partnership focuses on radioligand therapy, cell therapy, and early-phase trials. Singapore General Hospital (SGH) and ...

Novartis operates as a single global operating segment. It is now concentrating on four core therapeutic areas — cardiovascular- renal-metabolic, immunology, neuroscience and oncology.

Sigma Planning Corp cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 19.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,218 shares of the company’s stock after ...